{"id":"NCT00750152","sponsor":"Merz North America, Inc.","briefTitle":"Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Cruris","officialTitle":"A Phase 3 Double-Blind, Randomized, Placebo-Controlled,Multicenter, Parallel Group Evaluation of the Efficacy and Safety of NAFT-500 in Subjects With Tinea Cruris","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-09","primaryCompletion":"2009-08","completion":"2010-02","firstPosted":"2008-09-10","resultsPosted":"2012-03-13","lastUpdate":"2013-04-22"},"enrollment":334,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Tinea Cruris","Jock Itch"],"interventions":[{"type":"DRUG","name":"NAFT-500","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"2","type":"PLACEBO_COMPARATOR"},{"label":"1","type":"EXPERIMENTAL"}],"summary":"A research study to compare the safety and effectiveness of an investigational medication called NAFT-500 to placebo (no active treatment), when used in subjects with tinea cruris, also known as jock itch.","primaryOutcome":{"measure":"Percentage of Subjects","timeFrame":"Week 4 post-baseline","effectByArm":[{"arm":"NAFT-500","deltaMin":25.3,"sd":null},{"arm":"Placebo-2wks","deltaMin":2.8,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.025"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":20,"countries":["United States","Puerto Rico"]},"refs":{"pmids":["21968664"],"seeAlso":["http://dailymed.nlm.nih.gov/"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":166},"commonTop":["Headache","Dyslipidaemia","Pruritus"]}}